Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Copperwynd Financial LLC

Copperwynd Financial LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 720 shares of the biopharmaceutical company’s stock after selling 78 shares during the period. Copperwynd Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $513,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Greykasell Wealth Strategies Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $504,000. Intact Investment Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $356,000. Atala Financial Inc acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $154,000. Madison Investment Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at about $4,591,000. Finally, Thompson Siegel & Walmsley LLC increased its stake in Regeneron Pharmaceuticals by 2.2% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 7,652 shares of the biopharmaceutical company’s stock worth $5,451,000 after acquiring an additional 162 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 2.0 %

NASDAQ:REGN opened at $666.87 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $72.91 billion, a price-to-earnings ratio of 17.42, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The stock has a 50-day simple moving average of $694.91 and a 200 day simple moving average of $836.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $11.86 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Wall Street Analysts Forecast Growth

REGN has been the subject of a number of research reports. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. UBS Group cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Leerink Partnrs raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, Sanford C. Bernstein lowered their price target on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.